CT-2103: emerging utility and therapy for solid tumours

Bibliography

• GIACCONE G, JOHNSON DH, MANEGOLD C et at: A Phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT-1). Ann. Oncol (2002) 13\(Suppl. 5):2.
   Google Scholar
• JOHNSON DH, HERBST R, GIACCONE G et al.: ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): initial results from a Phase III trial (INTACT-2). Ann. Oncol (2002) 13\(Suppl. 5):127.
   Google Scholar
• SMYLIE M, MERCIER R, ABOULAFIA D et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Chu. Oncol (2001) 20:307a (Abstract 1226).
   Google Scholar
• LYNCH TJ Jr, RAJU R, LIND M et al.: Randomized Phase II trial of chemotherapy and antisense oligonucleotide LY 900003 (ISIS 3521) in patients with advanced NSCLC. 10th World Conference on Lung Cancer Vancouver, Canada (2003).
   Google Scholar
• MAEDA H, WU J, SAWA T et al: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Control Release (2000) 65:271.
   PubMed Web of Science ®Google Scholar
• SINGER JW, BAKER B, DE VRIES P et al.: Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. (2003) 519:81–99.
   Google Scholar
• •Article provides valuable background material on CT-2103 including pre-clinical pharmacology and early clinical activity and safety. Expert Op/n. lnvestig. Drugs (2004)13(11)1507
   Google Scholar
• SHAFFER SA, BAKER LEE C, NUDELMAN E et al.: Metablolism of poly-L-glutamic acid (PG) paclitaxel (CT-2103): proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Proc. Am. Assoc. Cancer Res. (2002) 43:416.
   Google Scholar
• VASEY PA, KAYE SB, MORRISON R et al.: Phase I clinical and pharmacokinetic study of PK1(2-hydroxypropyl)methacrylamide copolymer doxorubicird: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. (1999) 5:83–94.
   PubMed Web of Science ®Google Scholar
• McCORMICK-THOMSON LA, DUNCAN R: Poly (amino acid) copolymers as a potential soluble drug delivery system. 1. Pinocytic uptake and lysosomal degradation measured in vitro. Bioactive Compatible Polymers. (1989) 4:242–251.
   Google Scholar
• LI C, PRICE JE, MILAS L et al: Antitumor activity of poly (L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. (1999) 5:891–897.
   PubMed Web of Science ®Google Scholar
• LI C, YU DF, NEWMAN RA et al: Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. (1998) 58:2404–2409.
   PubMed Web of Science ®Google Scholar
• •Experimental models corroborate the activity of polyglutamate paclitaxel, underscoring its potential utility in clinical trials.
   Google Scholar
• LI C, NEWMAN RA, WU QP et al: Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol (2000) 46:416–422.
   PubMed Web of Science ®Google Scholar
• OLDHAM E, LI C, KE S, WALLACE S, HUANG P: Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol (2000) 16:125–132.
   PubMed Web of Science ®Google Scholar
• Cell Therapeutics, Inc. (Data on Me).
   Google Scholar
• LI C, KE S, WU Q et al: Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. Int. Radiat. Oncol Biol. Phys. (2000) 48:1119–1126.
   PubMed Web of Science ®Google Scholar
• KE S, MILAS L, CHARNSANGAVEJ C, WALLACE S, LI C: Potentiation of radiorespnose by polymer-drug conjugates. J. Control Release. (2001) 74:237–242.
   PubMed Web of Science ®Google Scholar
• MILAS L, MASON KA, HUNTER N, LI C, WALLACE S: Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. bit. .1 Radiat. Oncol Biol. Phys. (2003) 55:707–712.
   Google Scholar
• BURRIS H, SHIPLEY D, GRECO A et a/.:Phase I study of XYOTAX" (CT-2103) in patients with non-small-cell lung cancer who are 70 years of age or performance status (PS) = 2 [abstract 806]. ECCO 12, The European Cancer Conference. Copenhagen, Denmark (2003) Abstract 555.
   Google Scholar
• SKUBITZ K, KUDELKA AP, BOLTON MG: Phase I study of XYOTAX" (CT-2103) and cisplatin in patients with solid tumors: preliminary data. ECCO 12, The European Cancer Conference. Copenhagen, Denmark (2003) Abstract 554.
   Google Scholar
• NEMUNAITIS J, BOLTON MG: Phase I study of XYOTAX" (CT-2103) and carboplatin in patients with solid tumors. ECCO 12, The European Cancer Conference. Copenhagen, Denmark (2003) Abstract 566.
   Google Scholar
• SABBATINI P, BROWN J, AGHAJANIAN C et al: Early findings in a Phase I/II study of PG-paclitaxel (CT-2103) in recurrent ovarian, fallopian tube, or peritoneal cancer. Proc. Am. Soc. Clinic. Oncol (2002) 21:A–871.
   Google Scholar
• REDFERN C, SCHULZ J, BURRIS H et al: Phase II study of XYOTAX" (CT-2103) in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen. ECCO 12, the European Cancer Conference. Copenhagen, Denmark (2003) Abstract.
   Google Scholar
• BURRIS H, SHIPLEY D, GRECO A et a/.:Phase I studies of CT-2103 in patients with non small cell lung cancer and with advanced malignancies. Eur. J. Cancer Suppl. (2003) 1(5):5168.
   Google Scholar
• BODKIN D, NEUBAUER M, BOLTON MG: Phase II study of first line chemotherapy using XYOTAX" (CT-2103) in patients with non-small-cell lung cancer who are 70 years of age or performance status (PS) = 2. ECCO 12. The European Cancer Conference. Copenhagen, Denmark (2003):Abstract 806.
   Google Scholar
• SWEENEY C, ZHU J, SANDLER AB et al.: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer (2001) 92:2639.
   PubMed Web of Science ®Google Scholar
• •The results of combination therapy in the cohort of PS 2 patients enrolled onto E1594 underscores their poor prognosis, Increased incidence of adverse events and the general therapeutic frustration in managing these patients.
   Google Scholar
• JIROUTEK M, JOHNSON D, BLUM R et al.: Prognostic factors in advanced NSCLC: analysis of ECOG trials from 1981–1992. Proc. Am. Soc. Clin. Oncol (1998) 17:A-1777 (Abstract 1774).
   Google Scholar
• LILENBAUM RC, HERNDON J, LIST M et al.: Single agent versus combination chemotherapy in advanced NSCLC: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc. Am. Soc. Chia. Oncol (2002) 21:A-2 (Abstract 2).
   Google Scholar
• •The Phase III randomised trial of the CALGB in advanced NSCLC demonstrated putative superiority for combination paclitaxel/carboplatin versus single-agent paclitaxel in the PS2 cohort, therefore justifying the trial design of STELLAR 3.
   Google Scholar